# CHICAGO MEDICAL RESEARCH, LLC.

**Name: Eden D. Brandon, MD**
Email: ebrandon@cmrllc1.com

## PROFESSIONAL EMPLOYMENT:

| | |
|---|---|
| 2015 - Present | Medical Director and Clinical Investigator, Chicago Medical Research, LLC, Hazel Crest, Illinois |
| 2006 - Present | Staff Physician, Chandra Diagnostic Cardiology, Ltd., Hazel Crest, Illinois |
| 2006 - Present | Internist, Ingalls Memorial Hospital, Harvey, Illinois |
| 1999 - 2006 | Staff Physician, House Call Services of Greater Chicago d/b/a MD at Home, Illinois |

## EDUCATION:

| | |
|---|---|
| 1993 | Doctor of Medicine, Northwestern University School of Medicine, Chicago, Illinois |
| 1993 - 1996 | Residency in Internal Medicine, Rush Presbyterian St. Luke's Medical Center, Chicago, Illinois |

## LICENSE AND CERTIFICATION:

| | |
|---|---|
| Medical License | State of Illinois - License No. 036.095540 |
| Board Certification | American Board of Internal Medicine - Internal Medicine |

## PROFESSIONAL MEMBERSHIPS:

- National Medical Fellowship
- Minority Affairs Committee
- American Academy of Homecare Physicians

## THERAPEUTIC AREA OF EXPERTISE:

| Therapeutic Area | Sub-Therapeutic Area |
|---|---|
| Cardiology | Coronary Artery Disease, Acute Coronary Syndrome, Myocardial Infarction, Hypertension, Hyperlipidemia |
| Nephrology | Chronic Kidney Disease |
| Pain Management | Chronic Low Back Pain |
| Orthopedics | Osteoarthritis |
| Endocrinology | Diabetes Mellitus Type II |

## CLINICAL TRIAL EXPERIENCE

1. **Protocol: 70033093AFL3002 (LIBREXIA-AF)** - A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation.
2. **Protocol: 1378-0020 (EASi-HF Preserved)** - A Phase III Double-Blind, Randomised, Parallel-Group Superiority Trial to Evaluate Efficacy and Safety of the Combined Use of Oral Vicadrostat (BI 690517) and Empagliflozin Compared With Placebo and Empagliflozin in Participants With Symptomatic Heart Failure (NYHA II-IV) and Left Ventricular Ejection Fraction >=40%.
3. **Protocol: EX6018-4758 (ZEUS)** - Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Participants With Established Atherosclerotic Cardiovascular Disease, Chronic Kidney Disease and Systemic Inflammation.
4. **Protocol: EX6018-4914 (ATHENA)** - Effects of Ziltivekimab Versus Placebo on Heart Failure Symptoms and Physical Function in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation.
5. **Protocol: EX6018-4915 (HERMES)** - Effects of Ziltivekimab Versus Placebo on Morbidity and Mortality in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation.

6. **Protocol: D6402C00012 (BalanceD-HF)** - A Phase III, Randomised, Double-Blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Compared With Dapagliflozin, on the Risk of Heart Failure Events and Cardiovascular Death in Patients With Heart Failure and Impaired Kidney Function.
7. **Protocol: D6972C00003 (ARCTIC)** - A Phase III, Randomised, Double-Blind Study to Assess the Efficacy, Safety, and Tolerability of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on Chronic Kidney Disease Progression in Participants With CKD and High Blood Pressure.
8. **Protocol: CV0291001 (BMS-986435/MYK-224 HFpEF)** - A Phase 2A, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction.
9. **Protocol: C4291003 (BRANCH-HF)** - A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Oral Branched Chain Ketoacid Dehydrogenase Kinase Inhibitor, PF-07328948, in Adults With Heart Failure.
10. **Protocol: ALN-AGT01-008 / US0006 (ZENITH)** - A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease.
11. **Protocol: ALN-AGT01-008 / US0096 (ZENITH)** - A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease.
12. **Protocol: 20230227 (MARITIME-HF)** - A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity.
13. **Protocol: VS-041-102 (VS-041 HFpEF)** - A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction.
14. **Protocol: 1378-0018 (EASi-HF Reduced)** - A Phase III Double-Blind, Randomised, Parallel-Group Superiority Trial to Evaluate Efficacy and Safety of the Combined Use of Oral Vicadrostat (BI 690517) and Empagliflozin Compared With Placebo and Empagliflozin in Participants With Symptomatic Chronic Heart Failure and Left Ventricular Ejection Fraction <40%.
15. **Protocol: NN9490-8266 (POLARIS)** - Efficacy and Safety of NNC0487-0111 Compared With Placebo on Morbidity and Mortality in People With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity.
16. **Protocol: NN9490-8665 (AMBITION 7)** - Efficacy and Safety of Zenagamtide Once Weekly Compared With Insulin Glargine Once Daily in Participants With Type 2 Diabetes and Increased Cardiovascular Risk Inadequately Controlled on One to Three Oral Glucose-Lowering Medications.
17. **Protocol: D9480C00018 (REALIZE)** - Double-Blind, Placebo-Controlled Evaluation of Sodium Zirconium Cyclosilicate for the Management of Hyperkalemia in Patients With Symptomatic Heart Failure With Reduced Ejection Fraction.
18. **Protocol: STEP-HFpEF-DM** - Effect of Semaglutide 2.4 mg Once Weekly on Function and Symptoms in Participants With Obesity-Related Heart Failure With Preserved Ejection Fraction and Type 2 Diabetes.
19. **Protocol: STEP-HFpEF** - Effect of Semaglutide 2.4 mg Once Weekly on Function and Symptoms in Participants With Obesity-Related Heart Failure With Preserved Ejection Fraction.

21. **Protocol: CRD-750-202** - A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Preserved Ejection Fraction.
22. **Protocol: CRD-750-201** - A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction.

**SIGNATURE & DATE:**

MD 06 Oct 2026